Call for Abstracts

Acceptance notice will be sent to the first author by email in the end of November.

If you are Japanese, please declare your COI and
submit your abstract at Japanese website.

Abstract Submission Period

Noon, Wednesday, June 17-
Noon, Wednesday, September 16, 2020,
Noon, Wednesday, September 30, 2020 (JST)

Abstract Submission has been closed.
Thank you for your submission.

Call for Abstracts

General Abstract (Oral / Poster Presentation)

JSMO2021 accepts abstracts for general Abstract.
Presentation style for Oral Sessions are either live or on-demand streaming.
Presentation style for Poster Sessions will be on-demand streaming.

Please select the abstract category from the list below. (The 1st & 2nd choices are required.)

Abstract Category for General Abstract

Category Sub-Category Presentation Style

01. Gastrointestinal Cancer

01-01. Esophageal Cancer

01-02. Gastric Cancer

01-03. Small Bowel Cancer

01-04. Colorectal Cancer

01-05. Other (Appendix Cancer, Anal Cancer, etc.)


02. Hepatobiliary/
Pancreatic Cancer

02-01. Liver Cancer

02-02. Gallbladder and Biliary Tract Cancer

02-03. Pancreatic Cancer


03. Lung Cancer/
Thoracic Cancer

03-01. Early Stage Non-Small Cell Lung Cancer/Perioperative Treatment

03-02. Locally Advanced Non-Small Cell Lung Cancer

03-03. Metastatic Non-Small Cell Lung Cancer/Chemotherapy

03-04. Metastatic Non-Small Cell Lung Cancer/Tyrosine Kinase Inhibitor

03-05. Metastatic Non-Small Cell Lung Cancer/Immunotherapy

03-06. Small Cell Lung Cancer

03-07. Other (Mesothelioma, Thymic Malignancies, etc.)


04. Hematologic Malignancies

04-01. Lymphoma

04-02. Leukemia

04-03. Other (Myeloma etc.)


05. Breast Cancer

05-01. Early Breast Cancer/Perioperative Therapy

05-02. Metastatic Breast Cancer


06. Gynecologic Cancer

06-01. Gynecologic Cancer


07. Genitourinary Cancer

07-01. Genitourinary Cancer


08. Head and Neck Cancer

08-01. Head and Neck Cancer


09. Rare Cancer/
Cancer of Unknown Primary

09-01. Pediatric Oncology

09-02. Central Nervous System Tumors

09-03. Endocrine Cancer, Thyroid Cancer, Neuroendocrine Tumor

09-04. Skin Cancer

09-05. Sarcoma

09-06. Germ Cell Tumor

09-07. Cancer of Unknown Primary

09-08. Other


10. Translational Research/
Clinical Pharmacology

10-01. Basic Research

10-02. Clinical Pharmacology

10-03. Innovative Drug Research & Development

10-04. Molecular Diagnostics/Genomic Medicine

10-05. Translational Research

10-06. Companion Diagnostics

10-07. Developmental Therapeutics

10-08. Other


11. Palliative Care/
Symptom Management

11-01. Palliative Medicine

11-02. Symptom Management

11-03. Oral Care for Cancer Patients

11-04. Psycho-Oncology

11-05. Other


12. Cross-sectional Program

12-01. Radiation Oncology

12-02. Diagnostic Imaging

12-03. Familial and Hereditary Cancer

12-04. Epidemiology

12-05. Cancer Prevention

12-06. Immunobiology and Immunotherapy

12-07. Drug Therapy

12-08. Other


13. Multidisciplinary Team Program

13-01. Interdisciplinary Approach to Cancer Care

13-02. Rehabilitation

13-03. Outpatient Chemotherapy

13-04. Professional Oncology Education

13-05. Oncology Nursing

13-06. Other


14. Clinical Trial Facilitation Program

14-01. Biostatistics

14-02. Clinical Trial Support

14-03. Trials in Progress

14-04. Research Ethics

14-05. Health Policy/Regulatory Affairs/Reimbursement

14-06. Health Technology Assessment/Health Economics

14-07. Other


15. Patient Advocacy/

15-01. Patient Advocacy

15-02. Survivorship

15-03. Geriatric Oncology

15-04. Community Cancer Care

15-05. Adolescents and Young Adults with Cancer

15-06. Other


16. Medical Case Report

16-01. Rare Cancer

16-02. Lung

16-03. Gastrointestinal Tract

16-04. Hematologic Malignancies

16-05. Breast

16-06. Solid Cancers


17. COVID-19 and cancer

17-01. COVID-19 and cancer



18-01. Miscellaneous


(a) Please note that if you select "Trials in Progress," your abstract will NOT be included in electronic program. Your submitted abstracts will be printed and handed out to the participants at the room where you deliver your presentation.

* Abstract Young Investigator Award

  • Age limitation: The first author must be under the age 40 (as of February 21, 2021)
  • Once you are nominated as a candidate, you will be requested to submit an electronic data for review in December 2020.
  • If you would like to be reviewed as a candidate, please check the box to be reviewed as the candidate for the Abstract Young Investigator Award.

* All submitted abstracts will be reviewed by the Peer Review Committee and decided comprehensively based on the study contents, ethical aspects, and etc. You may choose the presentation style (oral or poster) when you submit an abstract. However, please understand that the congress president will make a final decision on the presentation style, presentation session, as well as acceptance/rejection.

Late-breaking Abstracts

JSMO2021 would like to deepen discussions based on the latest research results. We accept such abstracts as "Late-breaking abstracts".

If you are applying for Late-breaking abstracts, please select "Yes" for the question, "Are you applying for late-breaking abstracts?" and submit an outline and predicted results of your research as interim registration in the abstract text box.
Please complete the abstract submission with the latest research results by Friday, October 30, 2020. (You will be notified by the Secretariat to complete the abstract submission at the beginning of October.)

* The accepted results are not influenced even if the actual research results were different from your prediction.

Presidential Session

JSMO2021 will select the abstracts for "Presidential Sessions" from the submitted abstracts this year instead of usual Plenary Session. The selection flow is as follows.

Step 1:

The program committee members choose the following number of abstracts from each category.

38 abstracts in total: 6 abstracts from each Gastrointestinal Cancer and Lung Cancer/Thoracic Cancer, and each 2 abstracts from other category.

Step 2:

Congress president selects 12 abstracts out of 38 abstracts, and the final selection will be made at the program committee.

There is one session a day, and each session is 120 minutes consisting of 4 presentations.

Each presentation is 30 minutes in total (presentation 15 min, Q&A 5 min and discussion 10 min).

Virtual Foreign Contribution Awards
(former Travel Awards)

2021 the Japanese Society of Medical Oncology Annual Meeting (JSMO 20201) will be held as a virtual congress. To support and promote greater interaction with clinicians and researchers from abroad, we will be awarding Virtual Foreign Contribution Awards in lieu of traditional Travel Awards. Exceptional abstracts will be selected, and winners will have their registration fees waived and will be recognized with an award and prize money. Applicants must have submitted an abstract for presentation in a poster or oral session. Applicants who have already submitted their abstracts do not need to re-submit.

Award Details

  • Congress registration to JSMO2021 is waived
  • Recognition award
  • Prize awards ranging from JPY 30,000

Application Acceptance Period

The application period is same as the general abstract submission period.
Noon, Wednesday, June 17, 2020 -

Noon, Wednesday, September 16, 2020, Japan Standard Time
Noon, Wednesday, September 30, 2020 (JST)

The application has been closed. Thank you for your application.

Eligible Applicants

  • Applicants must be young overseas doctors/researchers, who live outside of Japan, age 45 years old or younger, as of February 21, 2021 (the last day of JSMO2021).
  • Applicants receiving commercial grant support or financial assistance are ineligible.

How to Apply

Please apply by submitting your abstract from the Submission Page (click the "Submit" button below).

Award Notification

Recipients will be notified by e-mail at the end of November, 2020

Publication in "Annals of Oncology"

Abstracts (oral/ poster) submitted in English for JSMO2021 will be published in ESMO/JSMO Scientific Journal, supplement to "Annals of Oncology" (Elsevier).
If you wish to have your abstract published in "Annals of Oncology," please select "Yes".

However, in case that there is any possibility of duplicate publication or encore publication, please refrain from selecting "Yes".

* Terms to be published in Journal "Annals of Oncology" as to poster presentation:

Oral presentations are free of charge but poster presentations are required 5,000JPY of the posting fee of "Annals of Oncology" in addition to the Congress registration fee.

You can cancel publication of the journal after the acceptance notice.
We will contact you to confirm your final intention when the presentation style is decided.

Disclosure of Conflict of Interest at 2021 the Japanese Society of Medical Oncology Annual Meeting

The presenter (the first author) and the principal investigator must disclose the name of any company or for-profit organization related to medicine they have a relationship with, defined as follows: in the following items (3) to (9), (11), (12), exceeding separately stipulated criteria, and (1), (2), (10), (13) if met. The subject period is from January 1, 2017 - December 31, 2019.

COI Disclosure Information

COI Policy (in revision)

Detailed Enforcement Regulations of COI (in revision)

For oral presentation, please use the slide below as a template to disclose conflict of interest.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster panel.

Template of slide(284KB)


If your study for this presentation is supported by research funds


If you are or have been an employee of a company
and/or a profit-making organization related to medicine


If you have earned >¥1,000,000/year as an officer or advisor
of a company and/or a profit-making organization related to medicine


If you hold>5% of the stock of a company and/or a profit-making organization related to medicine, or receive dividends >¥1,000,000/year


If you have earned >¥1,000,000/year as a patent fee from a company and/or a profit-making organization related to medicine


If you have earned >¥500,000/year as a lecture fee from a company and/or a profit-making organization related to medicine


If you have earned >¥500,000/year as a manuscript fee from a company and/or a profit-making organization related to medicine


If you have research expenses >¥1,000,000/year from a company and/or a profit-making organization related to medicine


If you have received >¥1,000,000/year as a certain contribution from
a company and/or a profit-making organization related to medicine


If you are or have been involved in a certain endowed chair funded by
a company and/or a profit-making organization related to medicine


If you have >¥1,000,000/year as a fee for expert comment, judgment or testimony in legal proceedings, or others from a company
and/or a profit-making organization related to medicine


If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research)equivalent to >¥50,000/year from a company and/or a profit-making organization related to medicine


If you are a representative of an organization for clinical study which receives research expenses(donation, contract, others)from a company and/or a profit-making organization related to medicine

Adobe Reader

To view the PDF files, you may need, "Adobe Reader"(Download Adobe Reader)

Inquiries regarding COI disclosure

The Secretariat of the Japanese Society of Medical Oncology


Ethical Principles for Declaring Ethical Matters of your Abstract

In order to review whether your abstract is conformed to the standard of applicable research ethics such as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on human genome and gene analysis", etc., JSMO ask you to declare the following items:

The content of your declaration will not affect the acceptance or rejection of your abstract.
Please submit to the following:

  • Does your study include medical research on human subjects, human material or human data? *Required
  • Does your study comply with the Declaration of Helsinki?
  • Was your study approved by an institutional review board before starting the research?

Abstract Submission

If you are Japanese, please declare your COI and
submit your abstract at Japanese website.


We accept abstracts submitted online only through the submission system.
You may enter the submission page from the "Abstract Submission" button at the bottom of this page.

  1. Author information and abstracts must be submitted in English.
  2. Abstract title must be up to 120 single-byte characters. (including spaces)
  3. Abstract text must be up to 2,000 single-byte characters. (including spaces)
  4. The maximum of 20 authors (first author & co-authors) can be registered.
  5. The maximum of 20 affiliations (including the affiliation of the first author) can be registered.
  6. Please structure your abstract as follows:
  7. Any chart or diagram cannot be included.
  8. Regarding the special characters, please refer ‘How to type special characters’ in the registration page.
  9. In the registration page, you will be asked to enter the information such as "Application for Late-breaking abstracts", "Application for Virtual Foreign Contribution Awards (former Travel Awards)", "Publication in Annals of Oncology" as well as COI information.

    * It is recommended that you prepare your abstract text by Word/ text file in advance, and then copy it on the registration page.

    * The abstract registration ID number and your password which will be required to confirm, modify, delete, and add abstracts will be issued and sent to the first author by email when you complete your abstract submission. Please make sure to register the correct email address and keep them by yourself.
    The congress secretariat will NOT keep track of your information.

Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission

You can access to confirm/modify/delete/add abstracts during the abstract submission period.
The ID number and password will be required to enter the “Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission” Page.

Acceptance/Rejection Notification

Notification of acceptance/rejection will be sent to the first author by email in the end of November, 2020.

Abstract Submission Page

Abstract Submission

Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission Page

Confirmation / Modification /
Deletion / Additional Submission

Inquiries for Abstract Submission

Congress Secretariat

c/o Congrès Inc.
3-6-13, Awajimachi, Chuo-ku, Osaka, 541-0047, Japan

Page Top

Page top